Lupin’s UK subsidiary gets MHRA approval to market generic version of Spiriva

26 Aug 2022 Evaluate

Lupin’s UK subsidiary -- Lupin Healthcare (UK) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market a generic version of Spiriva. Lutio has the potential to offer significant cost savings when available to UK patients.

Tiotropium is used to relieve wheezing, shortness of breath, coughing, and chest tightness in patients with chronic obstructive pulmonary disease (COPD), a group of diseases that affect the lungs and airways) such as chronic bronchitis and emphysema. This is the second inhalation product by Lupin Healthcare for the UK market after Luforbec pressurised metered dose inhaler (pMDI).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2322.45 68.55 (3.04%)
20-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1777.45
Dr. Reddys Lab 1298.95
Cipla 1255.85
Zydus Lifesciences 890.60
Lupin 2322.45
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×